Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02282735 · ClinicalTrials.gov registry record
Parental Decision-Making for Children With Relapsed Neuroblastoma
A clinical trial of Relapsed Neuroblastoma, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- 96
- Enrollment target
- 9
- Study locations
NCT02282735: Active study of Relapsed Neuroblastoma, sponsored by Dana-Farber Cancer Institute.
NCT02282735 is a study of Relapsed Neuroblastoma that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 96 participants, above the 44-participant average among 8 other Relapsed Neuroblastoma trials with a reported enrollment target (118% higher). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02282735, a study of Relapsed Neuroblastoma, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 96 participants
- Enrollment target
- 9
- Study locations
Study Summary
Parental decision-making for children with advanced cancer is complex. Many parents have overly optimistic beliefs about prognosis and as a result choose aggressive measures even at the end of life, which are associated with greater suffering. Yet most parents wish to limit suffering, and in retrospect, many regret choices for cancer treatment for advanced cancer. These findings suggest that parents do not always have the information they need to make decisions that reflect their preferences. The proposed study will evaluate parental decision-making in advanced cancer, addressing gaps in the literature in 3 important respects. 1) Previous work on decision-making for children with advanced cancer has typically looked at decisions at one point in time, often asking parents to reflect on decisions after the child's death, even though parents' understanding of prognosis and decisions about care evolve over time. We will evaluate parental decision-making for advanced cancer over time. 2) Existing work focuses on aggressive end-of-life care as the worst possible outcome. However, some parents wish to pursue aggressive measures even when they recognize that the child has little chance for cure. We will evaluate the extent to which parental decision-making is informed and consonant with preferences, regardless of whether decisions lead to aggressive or palliative care. 3) Previous studies have focused on groups of different childhood cancers, making it difficult to ascertain whether differences in decision-making reflect differences in diseases, options for care, or parent preferences. We will focus on a single disease, relapsed neuroblastoma, as a model for parental decision-making.
Primary Outcome
Questionnaire-based measure
Conditions Studied
Study Locations (9)
California
- Children's Hospital of Los Angeles - Los Angeles
- Stanford/Packard's Children's Hospital - Palo Alto
Illinois
- The University of Chicago Medical Center - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Columbia University Medical Center - New York
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Tennessee
- St. Jude Children's Research Hospital - Memphis
Texas
- Cook's Children's Healthcare System - Fort Worth
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2013-05 |
| Est. Completion | 2027-06 |
What the registry record for NCT02282735 still lists
NCT02282735 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 96 participants, a relatively small participant target, above the 44-participant average among 8 other Relapsed Neuroblastoma trials with a reported enrollment target (118% higher).
The record links to 1 condition, with Relapsed Neuroblastoma appearing as the primary indexed condition, and to 0 interventions.
NCT02282735 lists 9 locations in 8 states (California, Illinois, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT02282735 about?
NCT02282735 is a clinical study titled "Parental Decision-Making for Children With Relapsed Neuroblastoma". Parental decision-making for children with advanced cancer is complex. Many parents have overly optimistic beliefs about prognosis and as a result choose aggressive measures even at the end of life, which are associated with greater suffering. Yet most parents wish to limit suffering, and in retrosp...
What is the current status of trial NCT02282735?
This trial is currently active not recruiting. The enrollment target is 96 participants. The study started on 2013-05. Estimated completion is 2027-06.
What conditions does trial NCT02282735 study?
This clinical trial studies the following conditions: Relapsed Neuroblastoma.
Who is sponsoring clinical trial NCT02282735?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02282735 being conducted?
This trial has 9 study locations across California, Illinois, Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02282735's enrollment target sits among peer trials
96 1st of 8 higher than 8 of 8 other Relapsed Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsed Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
RECRUITING · Phase 1
-
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
RECRUITING · Phase 1
-
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
RECRUITING · Phase 1
-
PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma
RECRUITING · Phase 1
-
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
RECRUITING · Phase 1
-
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia